Histology of Functional Density in Postmenopausal Breast
| Status: | Enrolling by invitation |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 40 - Any |
| Updated: | 1/5/2019 |
| Start Date: | November 2010 |
| End Date: | March 2019 |
Pilot Study to Examine Histological Characteristics of Mammographic Density With Molecular Breast Imaging: Part 1 - Postmenopausal Women
Increased mammographic density is recognized as an important risk factor for developing
breast cancer, however, the underlying mechanism explaining this relationship is unclear. The
investigators hypothesize that Molecular Breast Imaging (MBI) can more accurately distinguish
dense tissue on mammography which is at high risk from dense tissue at low risk by indicating
cellular activity in dense tissue as radiotracer uptake (functional density) in the breast.
In this pilot study, the investigators want to compare the histological characteristics of
breast tissue in patients with who have similar density on mammography but different levels
of functional density on MBI.
breast cancer, however, the underlying mechanism explaining this relationship is unclear. The
investigators hypothesize that Molecular Breast Imaging (MBI) can more accurately distinguish
dense tissue on mammography which is at high risk from dense tissue at low risk by indicating
cellular activity in dense tissue as radiotracer uptake (functional density) in the breast.
In this pilot study, the investigators want to compare the histological characteristics of
breast tissue in patients with who have similar density on mammography but different levels
of functional density on MBI.
Inclusion Criteria:
1. Age 40 or older
2. Be postmenopausal as defined as having at least 12 consecutive months of amenorrhea
3. Screening mammogram performed at Mayo Clinic Rochester within one year prior to the
current MBI study which demonstrates
1. Negative or benign assessment (BIRADs category 1-2)
2. No proliferative benign lesions (e.g. fibroadenomas) identified
3. Heterogeneously dense or extremely dense parenchyma (BIRADs density category 3 or
4)
4. MBI performed less than one month prior to biopsy demonstrating either significant FD
or photopenic FD.
Exclusion criteria:
1. Using any exogenous hormones (e.g., hormonal contraceptives, sex steroid hormones) or
any estrogen receptor modulating drugs (e.g., tamoxifen, raloxifene) or any aromatase
inhibitors within six months prior to study biopsy.
2. Personal history of any cancer, except non-melanomatous skin cancer
3. Current breast symptoms
4. Breast implants
5. Known allergy to local anesthetic.
6. History of bleeding complications from prior interventions
7. Current use of anticoagulants (e.g., Coumadin or other blood thinners)
8. Major medical condition
We found this trial at
1
site
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
Click here to add this to my saved trials
